Amgen v Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies

A US court’s recent decision to find in favor of Sanofi and invalidate Amgen's broad antibody patent claims has biotech manufacturers concerned about how to preserve their IP.